Asian Fund for Cancer Research Limited – AFCR shared a post on LinkedIn:
“Cell and gene therapies are advancing quickly. The next challenge is making them work safely and effectively for more patients.
At the AFCR Symposium at BIOHK2026, experts explored the practical questions shaping the field—from T-cell therapy and gene editing to local manufacturing, AI-enabled GMP systems, regenerative medicine and precision oncology.
Chaired by Dr. Sujuan Ba, Founder, President and CEO of AFCR, the symposium focused not only on what these therapies can do, but also on what it will take to manufacture them reliably, navigate regulatory pathways and bring them into broader clinical use.
The symposium concluded with the panel discussion ‘The Last Mile to Market,’ highlighting the need for earlier collaboration among regulators, manufacturers and developers to help advanced therapies move forward responsibly.
The next frontier is not only better science—it is building the systems that allow that science to reach more patients safely and deliver better outcomes.
Other posts about AFCR on OncoDaily.